Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacubitril/valsartan vs Valsartan in Resistant Hypertension
NCT05545059Phase 3Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Sep 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sacubitril + valsartan in resistant hypertension (RH) (2 arms), sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Change in 24 hours average ambulatory systolic blood pressure at 8 weeks. Status: unknown.
02
Drugs
sacubitril + valsartan
03
Conditions
resistant hypertension (RH)
Beyond the preview
Go deeper on NCT05545059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05545059.